BACKGROUND: The appropriate adjuvant treatment for resected pancreatic cancer remains a controversy. We sought to determine the effect of adjuvant treatment on overall survival (OS) in patients with pancreatic tail adenocarcinoma. METHODS: Retrospective review of patients with upfront surgically resected pancreatic tail cancer treated at our institution between 2000-2012 was performed to determine outcomes of patients treated with and without adjuvant radiation therapy (RT). Survival curves were calculated according to the Kaplan-Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) were performed using the Cox proportional hazards model. RESULTS: Thirty-four patients met inclusion criteria. 79% received adjuvant chemotherapy, either concurrent with RT or alone. The groups were well matched, with the only significant difference being patient sex. On both UVA and MVA there was significantly worse survival in patients with a post-op CA19-9 >90 [hazard ratio (HR) 5.55; 95% confidence interval (CI): 1.20-25.7, P=0.03] and improved survival in patients treated with adjuvant RT (HR 0.15; 95% CI: 0.04-0.58, P=0.006). The median and 2-year OS were 21.6 months and 47% for patients treated with adjuvant RT compared with 11.3 months and 21% for those treated without RT. CONCLUSIONS: Although few in patient numbers, this data suggests integration of adjuvant RT in resected pancreatic tail adenocarcinoma may improve OS.
BACKGROUND: The appropriate adjuvant treatment for resected pancreatic cancer remains a controversy. We sought to determine the effect of adjuvant treatment on overall survival (OS) in patients with pancreatic tail adenocarcinoma. METHODS: Retrospective review of patients with upfront surgically resected pancreatic tail cancer treated at our institution between 2000-2012 was performed to determine outcomes of patients treated with and without adjuvant radiation therapy (RT). Survival curves were calculated according to the Kaplan-Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) were performed using the Cox proportional hazards model. RESULTS: Thirty-four patients met inclusion criteria. 79% received adjuvant chemotherapy, either concurrent with RT or alone. The groups were well matched, with the only significant difference being patient sex. On both UVA and MVA there was significantly worse survival in patients with a post-op CA19-9 >90 [hazard ratio (HR) 5.55; 95% confidence interval (CI): 1.20-25.7, P=0.03] and improved survival in patients treated with adjuvant RT (HR 0.15; 95% CI: 0.04-0.58, P=0.006). The median and 2-year OS were 21.6 months and 47% for patients treated with adjuvant RT compared with 11.3 months and 21% for those treated without RT. CONCLUSIONS: Although few in patient numbers, this data suggests integration of adjuvant RT in resected pancreatic tail adenocarcinoma may improve OS.
Entities:
Keywords:
Pancreatic tail; adjuvant radiation; pancreatic cancer
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2017-08 Impact factor: 11.908
Authors: Martha L Slattery; Erica Wolff; Michael D Hoffman; Daniel F Pellatt; Brett Milash; Roger K Wolff Journal: Genes Chromosomes Cancer Date: 2010-12-16 Impact factor: 5.006
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Adam C Berger; Miguel Garcia; John P Hoffman; William F Regine; Ross A Abrams; Howard Safran; Andre Konski; Alan B Benson; John MacDonald; Christopher G Willett Journal: J Clin Oncol Date: 2008-11-24 Impact factor: 44.544
Authors: C N Hurt; S Falk; T Crosby; A McDonald; R Ray; G Joseph; J Staffurth; R A Abrams; G Griffiths; T Maughan; S Mukherjee Journal: Br J Cancer Date: 2017-04-04 Impact factor: 7.640